Biocon climbs 5% on launch of Ogivri biosimilar in US market
newsdepo.com
Ogivri is used to treat breast cancer and gastric cancer and Biocon has regulatory approval to sell it in more than 80 countries worldwide.Biocon climbs 5% on launch of Ogivri biosimilar in US market
Ogivri is used to treat breast cancer and gastric cancer and Biocon has regulatory approval to sell it in more than 80 countries worldwide. Read more